OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Psychopharmacology is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
The dosing procedure that “makes the poison”: Comparing the effects of single versus cumulative alcohol administration methods on emotion recognition	270
Which are the demographic and clinical characteristics of patients who respond to subcutaneous esketamine?	192
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders	111
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation	101
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study	75
Glutamate levels across deep brain structures in patients with a psychotic disorder and its relation to cognitive functioning	74
The chronic effects of a combination of herbal extracts (Euphytose^®) on psychological mood state and response to a laboratory stressor: A randomised, placebo-controlled, double blind study	66
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat	59
Circadian rhythmicity in prepulse inhibition of the acoustic startle response: A study of chronotype and time-of-day effects in young healthy adults	57
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies	56
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study	56
Relationship between depression, prefrontal creatine and grey matter volume	49
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice	49
Psychedelics and the ‘inner healer’: Myth or mechanism?	45
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study	44
Co-use of psychedelics with other substances: Findings from the global psychedelic survey	44
Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a	42
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care	40
Associations between regular cannabis use and brain resting-state functional connectivity in adolescents and adults	40
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats	37
The Journal of Psychopharmacology: La Plus ça change. . .	36
Effects of 31 recombinant CYP2C19 variants on clomipramine metabolism in vitro	36
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine	36
Repurposing psychopharmacology: A two-way street?	34
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model	33

Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	33
A framework for assessment of adverse events occurring in psychedelic-assisted therapies	33
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy	33
Voluntary nicotine consumption and reward in a subset of diversity outbred founder strains	32
Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment	32
Impaired discrimination of a subanesthetic dose of ketamine in a maternal immune activation model of schizophrenia risk	30
Not too quick on “Debunking the myth of ‘Blue Mondays’”	30